查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1696289

全球人工胰臟系统市场 - 2025 至 2033 年

Global Artificial Pancreas System Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球人工胰臟系统市场规模达到 4.5697 亿美元，预计到 2033 年将达到 63.047 亿美元，2025-2033 年预测期内的复合年增长率为 30.0%。

人工胰臟系统是一种自动控制第一型糖尿病患者血糖的医疗设备。它包括连续血糖监测仪、胰岛素帮浦和先进的控制演算法。该系统模仿健康胰臟的功能，确保最佳血糖水平并降低高血糖和低血糖的风险。它改善了糖尿病管理和患者的便利性，并最大限度地减少了手动注射胰岛素的需要。

市场动态：

驱动因素与约束因素

糖尿病盛行率上升

全球糖尿病的流行，尤其是第1型糖尿病，正在推动人工胰臟系统市场的发展。许多醣尿病患者需要持续的血糖管理，因此对自动化解决方案的需求很大。感测器技术的进步改善了胰岛素的输送，人工智慧驱动的演算法透过提供高效、个人化的糖尿病管理解决方案促进了市场成长。

例如，根据国际糖尿病基金会的预测，到 2045 年，糖尿病盛行率将增加 46%，超过 90% 的患者患有第 2 型糖尿病。导致这种增长的因素包括城市化、人口老化、体力活动减少以及超重和肥胖的增加，而社会经济、人口、环境和遗传因素则加剧了这些因素的出现。

因此，糖尿病盛行率的增加将推动对人工胰臟装置系统的需求。这种需求，加上城市化和生活方式相关的风险因素，需要先进的血糖管理解决方案，从而导致自动胰岛素输送市场的扩大。

人工胰臟系统成本高昂

儘管人工胰臟系统在糖尿病管理方面具有潜在益处，但在市场扩张方面仍面临重大障碍，尤其是在中低收入国家。先进组件的高成本、有限的报销政策以及高昂的维护成本进一步限制了其采用，限制了其广泛使用。例如，带有 Control-IQ 的 Tandem t:slim X2 泵售价约为 4,000 美元，保险通常可承担 80% 的费用。 Dexcom G6 CGM 耗材（例如发射器和感测器）的额外成本可能相当高。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与关键要点

第三章：市场亮点与策略要点

  • 主要趋势和未来预测
  • 按设备类型分类的程式码片段
  • 最终用户的程式码片段
  • 按地区分类的片段

第 4 章：动态

  • 影响因素
    • 驱动程式
      • 糖尿病盛行率上升
      • 穿戴式和人工智慧医疗设备的普及率不断提高
    • 限制
      • 人工胰臟系统成本高昂
      • 严格的监管要求和审批延迟
    • 机会
      • 人工智慧与机器学习的融合，实现个人化糖尿病管理
    • 影响分析

第五章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的成熟领导者
    • 拥有成熟产品的市场领导者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT 分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第 6 章：按装置类型

  • 阈值暂停设备系统
  • 仅胰岛素系统
  • 双重荷尔蒙系统

第 7 章：按最终用户

  • 医院
  • 诊所
  • 家庭护理设置
  • 门诊手术中心

第 8 章：区域市场分析与成长机会

第九章：简介

  • 北美洲
    • 各区域关键动态
      • 我们
      • 加拿大
  • 欧洲
    • 各区域关键动态
      • 德国
      • 英国
      • 法国
      • 西班牙
      • 义大利
      • 欧洲其他地区
  • 拉丁美洲
    • 各区域关键动态
      • 墨西哥
      • 巴西
      • 阿根廷
      • 拉丁美洲其他地区
  • 亚太
    • 各区域关键动态
      • 中国
      • 印度
      • 日本
      • 韩国
      • 亚太其他地区
  • 中东和非洲
    • 各区域关键动态

第 10 章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
    • 市占率分析与定位矩阵
    • 策略伙伴关係、併购
    • 产品组合和创新的关键发展
    • 公司基准化分析

第 11 章：公司简介

  • Medtronic Plc
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售量
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
      • 关键进展
      • 合併与收购
      • 关键产品开发活动
      • 监管部门批准等
      • SWOT 分析
  • Tandem Diabetes Care, Inc
  • Beta Bionics
  • Insulet Corporation
  • Diabeloop
  • Inreda Diabetic BV
  • Nikkiso Co., Ltd(LIST NOT EXHAUSTIVE)

第 12 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 13 章：附录

简介目录
Product Code: MD9415

The global artificial pancreas system market reached US$ 456.97 million in 2024 and is expected to reach US$ 6304.70 million by 2033, growing at a CAGR of 30.0% during the forecast period 2025-2033.

Artificial pancreas system is a medical device that automates blood glucose control in type 1 diabetes patients. It includes a continuous glucose monitor, insulin pump, and advanced control algorithm. This system mimics the function of a healthy pancreas, ensuring optimal blood sugar levels and reducing the risk of hyperglycemia and hypoglycemia. It improves diabetes management and patient convenience and minimizes the need for manual insulin administration.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Diabetes

The global diabetes prevalence, particularly type 1, is driving the artificial pancreas system market. Many diabetes patients need continuous blood glucose management, leading to a demand for automated solutions. Advancements in sensor technology improved insulin delivery, and AI-driven algorithms are contributing to market growth by offering efficient, personalized diabetes management solutions.

For instance, according to International Diabetes Foundation by 2045, IDF projections indicate a 46% increase in diabetes prevalence, with over 90% of individuals having type 2 diabetes. Factors contributing to this increase include urbanization, an aging population, decreased physical activity, and an increase in overweight and obesity, which are exacerbated by socio-economic, demographic, environmental, and genetic factors.

Hence, an increase in the prevalence of diabetes will drive demand for artificial pancreas device systems. This demand, coupled with urbanization and lifestyle-related risk factors, necessitates advanced glucose management solutions, leading to market expansion for automated insulin delivery.

High Cost of Artificial Pancreas Systems

Artificial pancreas systems, despite their potential benefits in diabetes management, face significant barriers to market expansion, particularly in low- and middle-income countries. The high cost of advanced components, limited reimbursement policies, and high maintenance costs further restrict adoption, limiting their widespread use. For instance, The Tandem t:slim X2 pump with Control-IQ costs around $4,000, with insurance typically covering 80% of the cost. Additional costs for Dexcom G6 CGM supplies, such as a transmitter and sensors, can be significant.

Segment Analysis

The global artificial pancreas system market is segmented based on device type, end-user, and region.

Device Type:

The threshold suspend device systems from the device type segment is expected to dominate the artificial pancreas system market with the highest market share

The threshold suspend and predictive suspend systems are tools that temporarily suspend insulin delivery when blood glucose levels drop below a pre-set level. These systems calculate blood glucose levels and stop delivering insulin before they reach too low. They do not automatically increase insulin doses. Storing insulin at the right moment can help prevent low blood sugar, or hypoglycemia, in individuals with type 1 diabetes. These systems may also assist those who develop hypoglycemia overnight, especially children.

The rise in diabetes, particularly type 1, is driving the adoption of Threshold Suspend Device Systems. This is driven by increased awareness of hypoglycemia risks and the need for automated insulin delivery systems. Technological advancements, regulatory approvals, healthcare expenditure, and expanded reimbursement policies in developed regions contribute to the adoption of these life-saving devices.

Geographical Analysis

North America is expected to hold a significant position in the artificial pancreas system market with the highest market share

North America dominates the threshold suspend device systems market due to advanced healthcare infrastructure, high diabetes management technologies, and key market players. The region's large type 1 diabetes population drives demand for automated insulin delivery solutions. Benefits from reimbursement policies, continuous glucose monitoring awareness, and technological advancements in insulin pumps drive market growth. Government initiatives, increased healthcare expenditure, and personalized medicine focus contribute to the growing adoption of Threshold Suspend Device Systems in North America.

Moreover, FDA approvals are also a significant factor that helps the region to grow during the forecast period. For instance, in May 2024, The U.S. Food and Drug Administration (FDA) approved an artificial pancreas developed by University of Cambridge researchers for use by individuals with type 1 diabetes, including during pregnancy, marking the first time the FDA has authorized the use of this life-changing app during pregnancy.

Moreover, in May 2023, the FDA approved the iLet Insulin-Only Bionic Pancreas System for individuals aged 6 and above with type 1 diabetes, an artificial pancreas system that autonomously determines and delivers insulin doses.

Competitive Landscape

The major global players in the artificial pancreas system market include Medtronic Plc, Tandem Diabetes Care, Inc., Beta Bionics, Insulet Corporation, Diabeloop, Inreda Diabetic B.V., and Nikkiso Co., Ltd among others.

Key Developments

  • In April 2024, the NHS launched a world-first initiative for tens of thousands of children and adults with type 1 diabetes in England, which will use an 'artificial pancreas' to monitor blood glucose levels and automatically adjust insulin dosage.

Why Purchase the Report?

  • Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global artificial pancreas system market report delivers a detailed analysis with 45key tables, more than 40 visually impactful figures and 165 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

3. Market Highlights and Strategic Takeaways

  • 3.1. Key Trends and Future Projections
  • 3.2. Snippet by Device Type
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Diabetes
      • 4.1.1.2. Growing Adoption of Wearable and AI-driven Healthcare Devices
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Artificial Pancreas Systems
      • 4.1.2.2. Stringent Regulatory Requirements and Approval Delays
    • 4.1.3. Opportunity
      • 4.1.3.1. Integration of AI and Machine Learning for Personalized Diabetes Management
    • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
    • 5.1.1. Emerging Pioneers and Prominent Players
    • 5.1.2. Established leaders with largest selling Brand
    • 5.1.3. Market leaders with established Product
  • 5.2. CXO Perspectives
  • 5.3. Latest Developments and Breakthroughs
  • 5.4. Case Studies/Ongoing Research
  • 5.5. Regulatory and Reimbursement Landscape
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. Porter's Five Force Analysis
  • 5.7. Supply Chain Analysis
  • 5.8. Patent Analysis
  • 5.9. SWOT Analysis
  • 5.10. Unmet Needs and Gaps
  • 5.11. Recommended Strategies for Market Entry and Expansion
  • 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.13. Pricing Analysis and Price Dynamics
  • 5.14. Key Opinion Leaders

6. By Device Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 6.1.2. Market Attractiveness Index, By Device Type
  • 6.2. Threshold Suspend Device Systems*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Insulin-only Systems
  • 6.4. Dual Hormone Systems

7. By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Clinics
  • 7.4. Homecare Settings
  • 7.5. Ambulatory Surgical Centers

8. Regional Market Analysis and Growth Opportunities

9. Introduction

  • 9.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.1. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Spain
      • 9.3.5.5. Italy
      • 9.3.5.6. Rest of Europe
  • 9.4. Latin America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Mexico
      • 9.4.5.2. Brazil
      • 9.4.5.3. Argentina
      • 9.4.5.4. Rest of Latin America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. South Korea
      • 9.5.5.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
    • 10.1.1. Market Share Analysis and Positioning Matrix
    • 10.1.2. Strategic Partnerships, Mergers & Acquisitions
    • 10.1.3. Key Developments in Product Portfolios and Innovations
    • 10.1.4. Company Benchmarking

11. Company Profiles

  • 11.1. Medtronic Plc*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue's
      • 11.1.3.1.1. Geographical Revenue Shares
      • 11.1.3.1.1.1. Revenue Forecasts
      • 11.1.3.1.2. Key Developments
      • 11.1.3.1.2.1. Mergers & Acquisitions
      • 11.1.3.1.2.2. Key Product Development Activities
      • 11.1.3.1.2.3. Regulatory Approvals, etc.
      • 11.1.3.1.3. SWOT Analysis
  • 11.2. Tandem Diabetes Care, Inc
  • 11.3. Beta Bionics
  • 11.4. Insulet Corporation
  • 11.5. Diabeloop
  • 11.6. Inreda Diabetic B.V
  • 11.7. Nikkiso Co., Ltd(LIST NOT EXHAUSTIVE)

12. Assumption and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us